Journal article
PET-based compartmental modeling of 124I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer
P Zanzonico, JA Carrasquillo, N Pandit-Taskar, JA O’Donoghue, JL Humm, P Smith-Jones, S Ruan, C Divgi, AM Scott, NE Kemeny, Y Fong, D Wong, D Scheinberg, G Ritter, A Jungbluth, LJ Old, SM Larson
European Journal of Nuclear Medicine and Molecular Imaging | SPRINGER | Published : 2015
Abstract
Purpose: The molecular specificity of monoclonal antibodies (mAbs) directed against tumor antigens has proven effective for targeted therapy of human cancers, as shown by a growing list of successful antibody-based drug products. We describe a novel, nonlinear compartmental model using PET-derived data to determine the “best-fit” parameters and model-derived quantities for optimizing biodistribution of intravenously injected 124I-labeled antitumor antibodies. Methods: As an example of this paradigm, quantitative image and kinetic analyses of anti-A33 humanized mAb (also known as “A33”) were performed in 11 colorectal cancer patients. Serial whole-body PET scans of 124I-labeled A33 and blood ..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
This study was supported by the Ludwig Center for Cancer Immunotherapy and National Institutes of Health (NIH) grant numbers P50 CA 86438-11 and PO1 CA 33049.